MARKET

COLL

COLL

Collegium Pharmaceutical Inc
NASDAQ
37.13
+0.42
+1.14%
After Hours: 37.30 +0.17 +0.46% 16:24 03/01 EST
OPEN
37.14
PREV CLOSE
36.71
HIGH
37.50
LOW
36.50
VOLUME
418.69K
TURNOVER
0
52 WEEK HIGH
37.79
52 WEEK LOW
20.83
MARKET CAP
1.19B
P/E (TTM)
32.22
1D
5D
1M
3M
1Y
5Y
Best Value Stocks to Buy for February 29th
NASDAQ · 3d ago
Collegium Pharmaceutical Q4: The Beat Goes On
Collegium Pharmaceutical, Inc. Stock rose over 10% last week after reporting better than expected quarterly results. The company has been paying down debt and repurchasing stock with its impressive operational cash flow. Collegium Pharmaceutical is a pain management company focused on the development of pain medications. The stock of the company rose 10% after the company reported better thanexpected quarterly results last week. We update our analysis around Collegium.
Seeking Alpha · 5d ago
Truist Securities Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $40
Benzinga · 6d ago
Truist Financial Sticks to Its Buy Rating for Collegium Pharmaceutical (COLL)
TipRanks · 6d ago
Weekly Report: what happened at COLL last week (0219-0223)?
Weekly Report · 6d ago
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has US$667.2m of debt on its balance sheet. The company uses debt to fund growth in its business. Collegium Pharmaceutical is growing its EBIT faster than former Australian PM Bob Hawke. The balance sheet is a good indicator of a company's ability to manage its debt. It has a low interest coverage of 2.5 times Collegium's net debt. But the company's free cash flow is higher than its debt levels.
Simply Wall St · 02/24 13:01
Where Collegium Pharmaceutical Stands With Analysts
Collegium Pharmaceutical (NASDAQ:COLL) underwent analysis by 5 analysts in the last quarter. The company has an average 12-month price target of $38.6. Collegium Pharmaceutical is a specialty pharmaceutical company that is developing abuse-deterrent drugs.
Benzinga · 02/23 19:01
Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN)
TipRanks · 02/23 12:31
More
About COLL
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta Products, Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The Nucynta Products are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. Belbuca is a buccal film that contains buprenorphine, a partial opioid agonist. Symproic is an oral formulation of naldemedine.

Webull offers Collegium Pharmaceutical Inc stock information, including NASDAQ: COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.